Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00074925" target="_blank" >RIV/00216224:14110/14:00074925 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/14:00061606

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s00277-013-1966-z" target="_blank" >http://dx.doi.org/10.1007/s00277-013-1966-z</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00277-013-1966-z" target="_blank" >10.1007/s00277-013-1966-z</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients

Popis výsledku v původním jazyce

This retrospective study evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced B-cell chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (B-PLL) to definitely describe the impact of this antibody in clinical routine use. Data were collected from 208 consecutive, mainly pretreated, patients with CLL (n=202), and B-PLL (n=6) who had received alemtuzumab. Response, progression-free survival (PFS), and overall survival (OS) in various settings were assessed,and toxicities were documented. In these routine patients, a comparably low cumulative dose of alemtuzumab (median,403 mg) was applied. In CLL, overall response rate was 32%, and various pre-therapeutic parameters were predictive for inferior response, among them, the prior administration of &gt;/- 3 therapy lines (P&lt;0.001), refractoriness to fludarabine (P=0.002), and bulky lymphadenopathy (P=0.003). PFS and OS after start of alemtuzumab were 6.2 and 21.0 months, respectively.

Název v anglickém jazyce

Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients

Popis výsledku anglicky

This retrospective study evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced B-cell chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (B-PLL) to definitely describe the impact of this antibody in clinical routine use. Data were collected from 208 consecutive, mainly pretreated, patients with CLL (n=202), and B-PLL (n=6) who had received alemtuzumab. Response, progression-free survival (PFS), and overall survival (OS) in various settings were assessed,and toxicities were documented. In these routine patients, a comparably low cumulative dose of alemtuzumab (median,403 mg) was applied. In CLL, overall response rate was 32%, and various pre-therapeutic parameters were predictive for inferior response, among them, the prior administration of &gt;/- 3 therapy lines (P&lt;0.001), refractoriness to fludarabine (P=0.002), and bulky lymphadenopathy (P=0.003). PFS and OS after start of alemtuzumab were 6.2 and 21.0 months, respectively.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Annals of Hematology

ISSN

0939-5555

e-ISSN

—

Svazek periodika

93

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

267-277

Kód UT WoS článku

000330208100010

EID výsledku v databázi Scopus

—